Conventional versus Hepatic Arteriography and C-Arm CT-Guided Ablation of Liver Tumors (HepACAGA): A Comparative Analysis
Authors:
- Niek WijnenNWNiek Wijnen
- Rutger C. G. BruijnenRBRutger C. G. Bruijnen
- Evert-Jan P. A. VonkenEVEvert-Jan P. A. Vonken
- Hugo W. A. M. de JongHJHugo W. A. M. de Jong
- Joep de BruijneJBJoep de Bruijne
- Guus M. BolGBGuus M. Bol
- Jeroen HagendoornJHJeroen Hagendoorn
- Martijn P. W. IntvenMIMartijn P. W. Intven
- Maarten L. J. SmitsMSMaarten L. J. Smits
Open Access
Abstract
Purpose: Hepatic Arteriography and C-Arm CT-Guided Ablation of liver tumors (HepACAGA) is a novel technique, combining hepatic–arterial contrast injection with C-arm CT-guided navigation. This study compared the outcomes of the HepACAGA technique with patients treated with conventional ultrasound (US) and/or CT-guided ablation. Materials and Methods: In this retrospective cohort study, all consecutive patients with hepatocellular carcinoma (HCC) or colorectal liver metastases (CRLM) treated with conventional US-/CT-guided ablation between 1 January 2015, and 31 December 2020, and patients treated with HepACAGA between 1 January 2021, and 31 October 2023, were included. The primary outcome was local tumor recurrence-free survival (LTRFS). Secondary outcomes included the local tumor recurrence (LTR) rate and complication rate. Results: 68 patients (120 tumors) were included in the HepACAGA cohort and 53 patients (78 tumors) were included in the conventional cohort. In both cohorts, HCC was the predominant tumor type (63% and 73%, respectively). In the HepACAGA cohort, all patients received microwave ablation. Radiofrequency ablation was the main ablation technique in the conventional group (78%). LTRFS was significantly longer for patients treated with the HepACAGA technique (p = 0.015). Both LTR and the complication rate were significantly lower in the HepACAGA cohort compared to the conventional cohort (LTR 5% vs. 26%, respectively; p < 0.001) (complication rate 4% vs. 15%, respectively; p = 0.041). Conclusions: In this study, the HepACAGA technique was safer and more effective than conventional ablation for HCC and CRLM, resulting in lower rates of local tumor recurrence, longer local tumor recurrence-free survival and fewer procedure-related complications.Keywords
This publication has 23 references indexed in Scilit:
- Hepatic Arteriography and C-Arm CT-Guided Ablation (HepACAGA) to Improve Tumor Visualization, Navigation and Margin Confirmation in Percutaneous Liver Tumor AblationCardioVascular and Interventional Radiology, 2023
- The Added Diagnostic Value of Transcatheter CT Hepatic Arteriography for Intraprocedural Detection of Previously Unknown Colorectal Liver Metastases During Percutaneous Ablation and Impact on the Definitive Treatment PlanCardioVascular and Interventional Radiology, 2023
- Colorectal liver metastasis: molecular mechanism and interventional therapySignal Transduction and Targeted Therapy, 2022
- BCLC strategy for prognosis prediction and treatment recommendation: The 2022 updateJournal of Hepatology, 2021
- Current role of ultrasound in the diagnosis of hepatocellular carcinomaJournal of Medical Ultrasonics, 2020
- Percutaneous Liver Tumour Ablation: Image Guidance, Endpoint Assessment, and Quality ControlCanadian Association of Radiologists Journal, 2018
- Transcatheter CT Hepatic Arteriography–Guided Percutaneous Ablation to Treat Ablation Site Recurrences of Colorectal Liver Metastases: The Incomplete Ring SignJournal of Vascular and Interventional Radiology, 2015
- Transcatheter CT Arterial Portography and CT Hepatic Arteriography for Liver Tumor Visualization during Percutaneous AblationJournal of Vascular and Interventional Radiology, 2014
- Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983European Journal of Cancer, 2014
- Incidence and Treatment of Local Site Recurrences Following RFA of Colorectal Liver MetastasesWorld Journal of Surgery, 2013